1
|
Lambert C, Da Silva S, Ceniti AK, Rizvi SJ, Foussias G, Kennedy SH. Anhedonia in depression and schizophrenia: A transdiagnostic challenge. CNS Neurosci Ther 2018; 24:615-623. [PMID: 29687627 DOI: 10.1111/cns.12854] [Citation(s) in RCA: 86] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 03/10/2018] [Accepted: 03/12/2018] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Anhedonia, as a dysregulation of the reward circuit, is present in both Major Depressive Disorder (MDD) and schizophrenia (SZ). AIMS To elucidate the clinical and neurobiological differences between schizophrenia (SZ) and depression (MDD) in regard to anhedonia, while reconciling the challenges and benefits of assessing anhedonia as a transdiagnostic feature under the Research Domain Criteria (RDoC) framework. METHODS In this review, we summarize data from publications examining anhedonia or its underlying reward deficits in SZ and MDD. A literature search was conducted in OVID Medline, PsycINFO and EMBASE databases between 2000 and 2017. RESULTS While certain subgroups share commonalities, there are also important differences. SZ may be characterized by a disorganization, rather than a deficiency, in reward processing and cognitive function, including inappropriate energy expenditure and focus on irrelevant cues. In contrast, MDD has been characterized by deficits in anticipatory pleasure, development of reward associations, and integration of information from past experience. Understanding the roles of neurotransmitters and aberrant brain circuitry is necessary to appreciate differences in reward function in SZ and MDD. CONCLUSION Anhedonia as a clinical presentation of reward circuit dysregulation is an important and relatively undertreated symptom of both SZ and MDD. In order to improve patient outcomes and quality of life, it is important to consider how anhedonia fits into both diagnoses.
Collapse
Affiliation(s)
- Clare Lambert
- Arthur Sommer Rotenberg Suicide and Depression Studies Program, St. Michael's Hospital, Toronto, ON, Canada.,Royal College of Surgeons in Ireland, School of Medicine, Dublin, Ireland
| | - Susana Da Silva
- Centre for Addiction and Mental Health, Toronto, ON, Canada.,Institute of Medical Science, University of Toronto, Toronto, ON, Canada
| | - Amanda K Ceniti
- Arthur Sommer Rotenberg Suicide and Depression Studies Program, St. Michael's Hospital, Toronto, ON, Canada.,Institute of Medical Science, University of Toronto, Toronto, ON, Canada
| | - Sakina J Rizvi
- Arthur Sommer Rotenberg Suicide and Depression Studies Program, St. Michael's Hospital, Toronto, ON, Canada.,Institute of Medical Science, University of Toronto, Toronto, ON, Canada.,Mental Health and Addiction Service, St. Michael's Hospital, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - George Foussias
- Centre for Addiction and Mental Health, Toronto, ON, Canada.,Institute of Medical Science, University of Toronto, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Sidney H Kennedy
- Arthur Sommer Rotenberg Suicide and Depression Studies Program, St. Michael's Hospital, Toronto, ON, Canada.,Institute of Medical Science, University of Toronto, Toronto, ON, Canada.,Mental Health and Addiction Service, St. Michael's Hospital, Toronto, ON, Canada.,Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| |
Collapse
|
2
|
Esumi S, Sagara H, Nakamoto A, Kawasaki Y, Gomita Y, Sendo T. Effect of GBR12909 on affective behavior: Distinguishing motivational behavior from antidepressant-like and addiction-like behavior using the runway model of intracranial self-stimulation. Behav Brain Res 2013; 243:313-21. [DOI: 10.1016/j.bbr.2012.10.051] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2012] [Revised: 10/11/2012] [Accepted: 10/18/2012] [Indexed: 10/27/2022]
|
3
|
Benaliouad F, Zhornitsky S, Rompré PP. Evidence that the reward attenuating effect of the D1-like antagonist, SCH-23390, is not mediated by its agonist action at the 5-HT2c receptors. Behav Brain Res 2010; 217:467-71. [PMID: 20920533 DOI: 10.1016/j.bbr.2010.09.023] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2010] [Revised: 09/17/2010] [Accepted: 09/21/2010] [Indexed: 11/28/2022]
Abstract
This study investigated the effect of the 5-HT2c receptor antagonist, SB-242,084, on the attenuation of brain stimulation reward by SCH-23390. An additional experiment determined the effectiveness of SB-242,084 at blocking the reward attenuating effect of 5-HT2c agonist, CP-809,101. Results show that SB-242,084 blocked the reward attenuating effect of CP-809,101 but failed to alter that of SCH-23390. These findings provide evidence that the agonist action of SCH-23390 at the 5-HT2c receptors does not contribute to its attenuating effect on reward.
Collapse
Affiliation(s)
- Faïza Benaliouad
- Département de Physiologie, Université de Montréal, Montréal, Canada H1N 3V2
| | | | | |
Collapse
|
4
|
Benaliouad F, Kapur S, Natesan S, Rompré PP. Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion. Eur Neuropsychopharmacol 2009; 19:416-30. [PMID: 19269794 DOI: 10.1016/j.euroneuro.2009.01.014] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2008] [Revised: 01/09/2009] [Accepted: 01/21/2009] [Indexed: 11/17/2022]
Abstract
Dysregulation of limbic dopamine (DA) neurotransmission results in abnormal positive or negative emotional states that characterize several mental disorders. Drugs that restore DA homeostasis are most likely to constitute effective treatments for such emotional disturbances. In this study, we investigated the effects of several doses of OSU-6162, a drug that belongs to a new class named "DA stabilizers", on brain stimulation reward. Because quinpirole produces, depending on the dose, a pre-synaptic depressant and a post-synaptic stimulatory effect on reward and locomotor activity, we also compared the ability of OSU-6162 and haloperidol to prevent these effects of the full DA agonist. Results show that OSU-6162 produced a dose-orderly reduction of reward with no change in the capacity of the animals to produce the operant response, and prevented, like haloperidol, both stimulatory and depressant effects of quinpirole on locomotor activity but only its reward stimulatory effect. The observed functional antagonism of OSU-6162 on these DA-dependent behaviors suggests that it may constitute an effective treatment for abnormal positive emotional state, and that it would be exempt of motor side-effects.
Collapse
Affiliation(s)
- Faïza Benaliouad
- Centre de recherche Fernand-Seguin de l'Hôpital Louis-H. Lafontaine Montréal, Canada; Département de physiologie, Université de Montréal, Montréal, Canada
| | | | | | | |
Collapse
|
5
|
Abstract
The effects of dopamine receptor agonists and antagonists on hyperlocomotion in mice induced by the nonpeptide delta-opioid receptor agonist (+)-4-[(aR)-a-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide) (SNC80) were investigated. SNC80 significantly increased locomotion (maximally at 2 mg/kg). In antagonism tests, naltrindole and naltriben completely attenuated this SNC80-induced hyperlocomotion, which suggests that SNC80-induced hyperlocomotion may be mainly mediated through delta-opioid receptors. Although haloperidol (dopamine D2-receptor antagonist) did not affect SNC80-induced hyperactivity, it inhibited morphine-induced hyperlocomotion. In combination tests, SNC80, at a dose that did not affect spontaneous activity, significantly potentiated hyperlocomotion induced by methamphetamine and the dopamine D1-receptor agonist 6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetra-hydro-1H-3-benzazepin hydrobromide (SKF81297), whereas the combination of SNC80 and the D2-like receptor agonist 7-OH-N,N-di-n-propyl-2-aminotetralin did not affect locomotor activity. An earlier study demonstrated that the combination of the D1-receptor agonist SKF81297 and the D2-like receptor agonist 7-OH-N,N-di-n-propyl-2-aminotetralin synergistically induced hyperactivity in mice. Therefore, the present findings suggest that stimulation of either D2-like receptors or delta-opioid receptors can enhance the hyperlocomotion induced by stimulation of D1 receptors by methamphetamine and SKF81297, and the mechanism that underlies the hyperactivity caused by SNC80 may be different from that which underlies the effects of morphine.
Collapse
|
6
|
Ito S, Mori T, Sawaguchi T. Differential effects of μ-opioid, δ-opioid and κ-opioid receptor agonists on dopamine receptor agonist-induced climbing behavior in mice. Behav Pharmacol 2006; 17:691-701. [PMID: 17110795 DOI: 10.1097/fbp.0b013e32801155a1] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Interactions between the dopaminergic system and opioids have not been adequately clarified. The present study was designed to investigate the effects of micro-opioid (morphine), delta-opioid (SNC80) and kappa-opioid (U50 488H) receptor agonists on dopamine receptor agonist-induced climbing behavior in mice. Apomorphine (dopamine-receptor agonist) increased stereotyped climbing behavior, unlike methamphetamine, morphine, U-50 488H and (+/-)7-hydroxy-N,N-di-n-propyl-2-aminotetralin hydrobromide (D2-like receptor agonist). Furthermore, SKF81297 (D1 receptor agonist) and SNC80 caused climbing behavior. In addition, while morphine (20 mg/kg), but not U50 488H or SNC80, significantly attenuated high-dose apomorphine (2.0 mg/kg)-induced climbing behavior, it significantly potentiated low-dose apomorphine (0.5 mg/kg)-induced climbing behavior. These results suggest that morphine may have dual effects on the behavioral effects induced by apomorphine. Furthermore, we interestingly showed that the combination of apomorphine or SKF81297 and SNC80 enhanced frequent nonstereotypic climbing behavior, suggesting that delta/D1 interactions may play a prominent role in the expression of certain types of behavior in mice. Thus, micro-opioid, delta-opioid and kappa-opioid receptor agonists induce possible differential effects on the dopaminergic system in mice.
Collapse
MESH Headings
- 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer/pharmacology
- Analgesics, Non-Narcotic/pharmacology
- Analgesics, Opioid/pharmacology
- Animals
- Apomorphine
- Benzamides/pharmacology
- Benzazepines
- Dopamine Agonists
- Male
- Mice
- Mice, Inbred Strains
- Morphine/pharmacology
- Motor Activity/drug effects
- Piperazines/pharmacology
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, kappa/agonists
- Receptors, Opioid, mu/agonists
- Tetrahydronaphthalenes
Collapse
Affiliation(s)
- Shinobu Ito
- Department of Legal Medicine, Tokyo Women's Medical University, Tokyo, Japan
| | | | | |
Collapse
|
7
|
Pak AC, Ashby CR, Heidbreder CA, Pilla M, Gilbert J, Xi ZX, Gardner EL. The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol 2006; 9:585-602. [PMID: 16942635 PMCID: PMC3732043 DOI: 10.1017/s1461145706006560] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/10/2005] [Revised: 01/13/2006] [Accepted: 01/17/2006] [Indexed: 11/05/2022] Open
Abstract
Increasing evidence suggests that enhanced dopamine (DA) neurotransmission in the nucleus accumbens (NAc) may play a role in mediating the reward and reinforcement produced by addictive drugs and in the attentional processing of drug-associated environmental cues. The meso-accumbens DA system is selectively enriched with DA D3 receptors, a DA receptor subtype increasingly implicated in reward-related brain and behavioural processes. From a variety of evidence, it has been suggested that selective DA D3 receptor antagonism may be a useful pharmacotherapeutic approach for treating addiction. The present experiments tested the efficacy of SB-277011A, a selective DA D3 receptor antagonist, in rat models of nicotine-enhanced electrical brain-stimulation reward (BSR), nicotine-induced conditioned locomotor activity (LMA), and nicotine-induced conditioned place preference (CPP). Nicotine was given subcutaneously within the dose range of 0.25-0.6 mg/kg (nicotine-free base). SB-277011A, given intraperitoneally within the dose range of 1-12 mg/kg, dose-dependently reduced nicotine-enhanced BSR, nicotine-induced conditioned LMA, and nicotine-induced CPP. The results suggest that selective D3 receptor antagonism constitutes a new and promising pharmacotherapeutic approach to the treatment of nicotine dependence.
Collapse
Affiliation(s)
- Arlene C Pak
- Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, MD 21224, USA
| | | | | | | | | | | | | |
Collapse
|
8
|
Thompson B, Leonard KC, Brudzynski SM. Amphetamine-induced 50kHz calls from rat nucleus accumbens: A quantitative mapping study and acoustic analysis. Behav Brain Res 2006; 168:64-73. [PMID: 16343652 DOI: 10.1016/j.bbr.2005.10.012] [Citation(s) in RCA: 140] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2005] [Revised: 10/17/2005] [Accepted: 10/21/2005] [Indexed: 11/30/2022]
Abstract
Emission of 50 kHz ultrasonic calls in rats is known to be associated with appetitive behavioural situations and positive social interactions. The purpose of the study was to pharmacologically characterize amphetamine-induced 50 kHz calls and to perform quantitative mapping of this response in the nucleus accumbens. Injections of amphetamine into the nucleus accumbens induced species-typical 50 kHz calls in adult rats. The acoustic parameters of the calls were not affected by different amphetamine doses or combination of agents. The increase in the number of calls occurred predominantly from the accumbens shell and to a lesser degree from the core region. This effect was dose-dependent within the range of 1-20 microg of amphetamine and was reversed by pretreatment with D1 or D2 dopamine antagonists (SKF-83566 or raclopride) administered to the same brain site. However, another D2 dopamine receptor antagonist, haloperidol, which is known to increase the accumbens dopamine level, was ineffective in reversing the increase in call number at the dose studied. On the contrary, intraacumbens haloperidol, when injected alone, caused an increase in 50 kHz calls. It is concluded that the release of dopamine, predominantly in the accumbens shell region, is responsible for production of 50 kHz calls and the calls may indicate an appetitive state compatible with anticipation of reward and positive affect. Both D1 and D2 subtypes of dopamine receptors may be necessary to induce 50 kHz calls and signal the appetitive state.
Collapse
Affiliation(s)
- Briar Thompson
- Department of Psychology and the Centre for Neuroscience, Brock University, St. Catharines, Ont. L2S 3A1, Canada
| | | | | |
Collapse
|
9
|
O'Brien CP, Gardner EL. Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Ther 2006; 108:18-58. [PMID: 16183393 DOI: 10.1016/j.pharmthera.2005.06.018] [Citation(s) in RCA: 119] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2005] [Accepted: 06/17/2005] [Indexed: 10/25/2022]
Abstract
Laboratory models, both animal and human, have made enormous contributions to our understanding of addiction. For addictive disorders, animal models have the great advantage of possessing both face validity and a significant degree of predictive validity, already demonstrated. Another important advantage to this field is the ability of reciprocal interplay between preclinical and clinical experiments. These models have made important contributions to the development of medications to treat addictive disorders and will likely result in even more advances in the future. Human laboratory models have gone beyond data obtained from patient histories and enabled investigators to make direct observations of human drug self-administration and test the effects of putative medications on this behavior. This review examines in detail some animal and human models that have led not only to important theories of addiction mechanisms but also to medications shown to be effective in the clinic.
Collapse
Affiliation(s)
- Charles P O'Brien
- Philadelphia VA Medical Center, Mental Illness Research and Education Center, 3900 Chestnut Street, Philadelphia, PA 19104, USA
| | | |
Collapse
|
10
|
Xi ZX, Gilbert JG, Pak AC, Ashby CR, Heidbreder CA, Gardner EL. Selective dopamine D3 receptor antagonism by SB-277011A attenuates cocaine reinforcement as assessed by progressive-ratio and variable-cost-variable-payoff fixed-ratio cocaine self-administration in rats. Eur J Neurosci 2005; 21:3427-38. [PMID: 16026480 PMCID: PMC3726031 DOI: 10.1111/j.1460-9568.2005.04159.x] [Citation(s) in RCA: 121] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
In rats, acute administration of SB-277011A, a highly selective dopamine (DA) D(3) receptor antagonist, blocks cocaine-enhanced brain stimulation reward, cocaine-seeking behaviour and reinstatement of cocaine-seeking behaviour. Here, we investigated whether SB-277011A attenuates cocaine reinforcement as assessed by cocaine self-administration under variable-cost-variable-payoff fixed-ratio (FR) and progressive-ratio (PR) reinforcement schedules. Acute i.p. administration of SB-277011A (3-24 mg/kg) did not significantly alter cocaine (0.75 mg/kg/infusion) self-administration reinforced under FR1 (one lever press for one cocaine infusion) conditions. However, acute administration of SB-277011A (24 mg/kg, i.p.) progressively attenuated cocaine self-administration when: (a) the unit dose of self-administered cocaine was lowered from 0.75 to 0.125-0.5 mg/kg, and (b) the work demand for cocaine reinforcement was increased from FR1 to FR10. Under PR (increasing number of lever presses for each successive cocaine infusion) cocaine reinforcement, acute administration of SB-277011A (6-24 mg/kg i.p.) lowered the PR break point for cocaine self-administration in a dose-dependent manner. The reduction in the cocaine (0.25-1.0 mg/kg) dose-response break-point curve produced by 24 mg/kg SB-277011A is consistent with a reduction in cocaine's reinforcing efficacy. When substituted for cocaine, SB-277011A alone did not sustain self-administration behaviour. In contrast with the mixed DA D(2)/D(3) receptor antagonist haloperidol (1 mg/kg), SB-277011A (3, 12 or 24 mg/kg) failed to impede locomotor activity, failed to impair rearing behaviour, failed to produce catalepsy and failed to impair rotarod performance. These results show that SB-277011A significantly inhibits acute cocaine-induced reinforcement except at high cocaine doses and low work requirement for cocaine. If these results extrapolate to humans, SB-277011A or similar selective DA D(3) receptor antagonists may be useful in the treatment of cocaine addiction.
Collapse
Affiliation(s)
- Zheng-Xiong Xi
- Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
| | - Jeremy G. Gilbert
- Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
| | - Arlene C. Pak
- Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
| | - Charles R. Ashby
- Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, Saint John’s University, Jamaica, NY 11439, USA
| | - Christian A. Heidbreder
- Department of Neuropsychopharmacology, Centre of Excellence for Drug Discovery in Psychiatry, GlaxoSmithKline Pharmaceuticals, 37135 Verona, Italy
| | - Eliot L. Gardner
- Neuropsychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, DHHS, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA
| |
Collapse
|
11
|
Abstract
dopamine D3 receptor is preferentially localized to the mesocorticolimbic dopaminergic system and has been hypothesized to play a role in cocaine addiction. To study the involvement of the D3 receptor in brain mechanisms and behaviors commonly assumed to be involved in the addicting properties of cocaine, the potent and selective D3 receptor antagonist trans-N-[4-[2-(6-cyano-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl] cyclohexyl]-4-quinolininecarboxamide (SB-277011-A) was administered to laboratory rats, and the following measures were assessed: (1) cocaine-enhanced electrical brain-stimulation reward, (2) cocaine-induced conditioned place preference, and (3) cocaine-triggered reinstatement of cocaine seeking behavior. Systemic injections of SB-277011-A were found to (1) block enhancement of electrical brain stimulation reward by cocaine, (2) dose-dependently attenuate cocaine-induced conditioned place preference, and (3) dose-dependently attenuate cocaine-triggered reinstatement of cocaine seeking behavior. Thus, D3 receptor blockade attenuates both the rewarding effects of cocaine and cocaine-induced drug-seeking behavior. These data suggest an important role for D3 receptors in mediating the addictive properties of cocaine and suggest that blockade of dopamine D3 receptors may constitute a new and useful target for prospective pharmacotherapies for cocaine addiction.
Collapse
|
12
|
Huang X, Lawler CP, Lewis MM, Nichols DE, Mailman RB. D1 dopamine receptors. INTERNATIONAL REVIEW OF NEUROBIOLOGY 2002; 48:65-139. [PMID: 11526741 DOI: 10.1016/s0074-7742(01)48014-7] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- X Huang
- Department of Neurology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA
| | | | | | | | | |
Collapse
|
13
|
Ragnauth A, Znamensky V, Moroz M, Bodnar RJ. Analysis of dopamine receptor antagonism upon feeding elicited by mu and delta opioid agonists in the shell region of the nucleus accumbens. Brain Res 2000; 877:65-72. [PMID: 10980244 DOI: 10.1016/s0006-8993(00)02674-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The nucleus accumbens (NAcc) has been implicated as an important reward site for the mediation of unconditioned reinforcers such as food. Although both mu-selective and delta-selective opioid agonists in the NAcc induce spontaneous and palatable feeding, these effects are mediated by multiple opioid receptor subtypes within the nucleus. A role for dopaminergic mediation of feeding in the NAcc is based upon selective antagonist-induced suppression of feeding induced by systemic amphetamine. The present study investigated whether feeding elicited by infusion of either mu ([D-Ala(2), NMe-Phe(4), Gly-ol(5)]-enkephalin) or delta(2) ([D-Ala(2), Glu(4)]-deltorphin) opioid receptor subtype agonists in the shell region of the NAcc would be modified by intra-accumbens pretreatment with equimolar (12-100 nmol) doses of either D(1)-selective (SCH23390) or D(2)-selective (raclopride) antagonists. Both opioid agonists displayed comparable magnitudes and durations of feeding responses in the NAcc. SCH23390 significantly and dose-dependently reduced mu agonist-induced feeding in the NAcc with significant reductions noted following the two higher, but not two lower doses. In contrast, raclopride pretreatment produced inconsistent effects upon mu agonist-induced feeding with limited actions across doses and test times. Further, neither SCH23390 nor raclopride pretreatment in the NAcc affected feeding elicited by the delta(2) opioid agonist. These data indicate that the role of dopamine receptors in mediating opioid-induced feeding within the shell region of the NAcc is both dependent upon the dopamine receptor subtype that was blocked (D(1) vs. D(2)) as well as the opioid receptor subtype which was being stimulated mu vs. delta(2)).
Collapse
MESH Headings
- Analgesics, Opioid/pharmacology
- Animals
- Dopamine Antagonists/pharmacology
- Eating/drug effects
- Eating/physiology
- Enkephalin, Ala(2)-MePhe(4)-Gly(5)-/pharmacology
- Male
- Nucleus Accumbens/drug effects
- Nucleus Accumbens/physiology
- Oligopeptides/pharmacology
- Rats
- Rats, Sprague-Dawley
- Receptors, Dopamine D1/drug effects
- Receptors, Dopamine D1/physiology
- Receptors, Dopamine D2/drug effects
- Receptors, Dopamine D2/physiology
- Receptors, Opioid, delta/agonists
- Receptors, Opioid, delta/physiology
- Receptors, Opioid, mu/agonists
- Receptors, Opioid, mu/physiology
Collapse
Affiliation(s)
- A Ragnauth
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, 65-30 Kissena Blvd., Flushing, NY 11367, USA
| | | | | | | |
Collapse
|
14
|
Tinsley MR, Rebec GV, Timberlake W. Facilitation of preparatory behavior in an artificial prey paradigm by D1-subfamily dopamine receptor activation. Behav Brain Res 2000; 114:23-30. [PMID: 10996043 DOI: 10.1016/s0166-4328(00)00188-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Dopamine agonists facilitate, and antagonists inhibit, conditioned preparatory behaviors in rats. Similar effects are demonstrated on an unconditioned preparatory behavior: predatory search and contact of a moving artificial prey stimulus. Apomorphine (0.1, 0.2 mg/kg), a direct agonist, had no effect relative to a within-subject injection of saline vehicle but d-amphetamine (0.1 mg/kg), an indirect agonist, increased contact frequency without altering overall motor activation. To determine the relative importance of the D1 and D2 subfamilies of receptors in the amphetamine effect, separate groups of animals received amphetamine co-injected with either SCH23390 (0.01 and 0.005 mg/kg) or eticlopride (0.01 mg/kg), D1 and D2 antagonists, respectively. Whereas the eticlopride-amphetamine group showed no change in contact frequency from baseline, co-injections of either dose of SCH23390 and amphetamine led to near total suppression of contact, as did treatment with SCH23390 (0.005 mg/kg) alone. Treatment with 0.01 mg/kg eticlopride alone increased contact frequency while treatment with a higher dose (0.1 mg/kg) had no effect. Treatment with the D1-subfamily agonist SKF81297 (0.1 mg/kg) increased contact frequency. Collectively, these results support the hypothesis that dopamine mediates unconditioned preparatory behavior and suggest differing roles for the D1 and D2 receptor subfamilies.
Collapse
Affiliation(s)
- M R Tinsley
- Center for the Integrative Study of Animal Behavior and Department of Psychology, Indiana University at Bloomington, 1101 E. Tenth St., Bloomington, IN 47405-7007, USA.
| | | | | |
Collapse
|
15
|
Simón VM, Parra A, Miñarro J, Arenas MC, Vinader-Caerols C, Aguilar MA. Predicting how equipotent doses of chlorpromazine, haloperidol, sulpiride, raclopride and clozapine reduce locomotor activity in mice. Eur Neuropsychopharmacol 2000; 10:159-64. [PMID: 10793317 DOI: 10.1016/s0924-977x(00)00070-5] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Distinguishing the specific effects of neuroleptics on one particular behaviour from its non-specific effects on motility is not easy. In this study, the effects of five neuroleptics on spontaneous motor activity were compared and the ED(50) values of these drugs to impair activity were calculated. Male and female mice were evaluated in an actimeter or in a shuttle-box used as an open field after the administration of chlorpromazine (0.4, 1.2, 3.6 mg/kg), haloperidol (0.1, 0.3, 0.9 mg/kg), raclopride (0.1, 0.3, 0.9 mg/kg), sulpiride (10, 30, 90 mg/kg) and clozapine (0.4, 1.2, 3.6 mg/kg), and two automatic and two observational activity measures were obtained. A very high correlation between automatic and observational measures, absence of sex differences, and a dose-dependent decrease of activity were observed with every compound. The results allow us to make accurate comparisons between these drugs in their potency in reducing spontaneous motor activity.
Collapse
Affiliation(s)
- V M Simón
- Area de Psicobiología, Facultad de Psicología, Universitat de València, Avda, Blasco Ibáñez, 21, 46010, Valencia, Spain
| | | | | | | | | | | |
Collapse
|
16
|
Mori T, Baba J, Ichimaru Y, Suzuki T. Effects of Rolipram, a Selective Inhibitor of Phosphodiesterase 4, on Hyperlocomotion Induced by Several Abused Drugs in Mice. ACTA ACUST UNITED AC 2000. [DOI: 10.1016/s0021-5198(19)30605-5] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
17
|
Abstract
The dopamine D(1) receptor agonist, R(+)-6-chloro-7, 8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF 81297), the dopamine D(2)/D(3) receptor agonist, trans-(-)-4aR-4,4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrazolo[3, 4-g]quinoline hydrochloride (quinpirole), and the dopamine D(3) receptor agonist, (+/-)-7-hydroxy-dipropylaminotetralin hydrobromide (7-OH-DPAT) all reduced the frequency of isolation-induced infant rat ultrasonic vocalizations and lowered body temperature when compared to saline-injected controls. Ultrasonic vocalization rate was not affected by either the dopamine D(1) receptor antagonist, R(+)-2,3,4, 5-tetrahydro-8-iodo-3-methyl-5-phenyl-1H-3-benzazepin-7-ol hydrochloride (SCH 23390) or the dopamine D(2)/D(3) receptor antagonist, S(-)-raclopride-L-tartrate (raclopride) when given alone, nor did these antagonists block the ultrasonic vocalization reductions caused by the dopamine D(1) receptor agonist or the dopamine D(2)/D(3) receptor agonist. The dopamine D(2)/D(3) receptor antagonist but not the dopamine D(1) receptor antagonist blocked the dopamine D(3) receptor agonist's ultrasonic vocalization reduction. SKF 81297 reduced general activity while quinpirole and 7-OH-DPAT increased activity. Raclopride reversed quinpirole's reduction in body temperature, as well as 7-OH-DPAT's effects on body temperature, ultrasonic vocalizations, and activity. These results indicate that dopamine D(1), D(2)/D(3), and D(3) receptor agonists all reduce ultrasonic vocalizations by as yet undetermined mechanisms.
Collapse
Affiliation(s)
- F N Dastur
- Department of Psychology, Dalhousie University, Halifax, Nova Scotia, Canada
| | | | | |
Collapse
|
18
|
Epping-Jordan MP, Markou A, Koob GF. The dopamine D-1 receptor antagonist SCH 23390 injected into the dorsolateral bed nucleus of the stria terminalis decreased cocaine reinforcement in the rat. Brain Res 1998; 784:105-15. [PMID: 9518570 DOI: 10.1016/s0006-8993(97)01190-6] [Citation(s) in RCA: 102] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The effects of bilateral intracranial injections of the D-1 dopamine receptor antagonist SCH 23390 HCl (0, 0.8, 1.6, 3.2, and 6.4 microgram total bilateral dose) administered into the dorsolateral bed nucleus of the stria terminalis (dlBNST) immediately prior to a 3 h intravenous cocaine self-administration session were examined. In addition, anatomical control injections of the most effective dose of SCH 23390 HCl (6.4 micogram) were made either 1.5 mm dorsal to the dlBNST or into the lateral ventricle. Injections directly into the dlBNST, but not those dorsal to the dlBNST or into the lateral ventricle, significantly increased the rate of cocaine self-administration within the first 20 min of the self-administration session, consistent with a partial attenuation of the reinforcing effects of cocaine under a fixed-ratio schedule of reinforcement (0.25 mg cocaine iv; fixed-ratio 5, timeout 20 s). Injections into all three sites increased cocaine self-administration across the entire 3 h session. These results suggest a role for D-1 dopamine receptors in the dlBNST in the reinforcing properties of self-administered cocaine, and also support the hypothesis that D-1 dopamine receptors in the 'extended amygdala' may play a significant role in cocaine self-administration.
Collapse
Affiliation(s)
- M P Epping-Jordan
- Department of Neuropharmacology, Division of Psychopharmacology, CVN-7, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA
| | | | | |
Collapse
|
19
|
Swanson CJ, Heath S, Stratford TR, Kelley AE. Differential behavioral responses to dopaminergic stimulation of nucleus accumbens subregions in the rat. Pharmacol Biochem Behav 1997; 58:933-45. [PMID: 9408198 DOI: 10.1016/s0091-3057(97)00043-9] [Citation(s) in RCA: 134] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The following experiments investigated the behavioral response to local microinfusion of dopamine (DA) and selective DA agonists into the core and shell subregions of the nucleus accumbens. Rats were implanted with chronic indwelling cannulae aimed at these subregions. Two experiments were conducted. In experiment 1, the response to DA (0, 2, 5, 10 microg/0.5 microl/side), the D-1 agonist SKF-82598 (0, 0.1, 1.0 microg), the D-2/3 agonist quinpirole (0, 1, 5, 15 microg) and the D-3 preferring agonist pramipexole (0.1, 1.0, 10.0 microg) was examined in photocell activity cages. Locomotor (horizontal) and rearing (vertical) activities were measured. DA and SKF-82958 induced relatively greater increases in activity following stimulation of the shell as compared with the core. Quinpirole induced a dose-dependent suppression of activity after infusion into both sites, although the core was more sensitive to the suppressive effect than the shell. Pramipexole induced time-dependent, biphasic effects that were small in magnitude and did not differentiate between site. In experiment 2, an observation procedure was used to record behaviors (locomotion, rearing, feeding, drinking). Dopamine (0, 2, 10 microg) elicited greater increases in rearing and feeding behavior in the shell than in the core. SKF-82958 (0, 0.75 microg) enhanced locomotion and rearing to a similar extent in both subregions in this test, whereas a mixture of a low dose (0.25 microg) of the D-1 and D-2 agonists selectively induced behavioral activation in the shell. In contrast to the results in the activity cage test, quinpirole (0, 1, 5 microg) increased motor activity at the lower dose when infused into the shell but not into the core. No alterations in feeding were observed following infusion of selective agonists, and no changes in drinking were found with any of the treatments. In summary, the shell appears to be relatively more sensitive to the motor activating effects of DA agonists than the core. Moreover, circuits associated with shell may be preferentially involved in feeding.
Collapse
Affiliation(s)
- C J Swanson
- Department of Psychiatry, University of Wisconsin-Madison Medical School, 53706, USA
| | | | | | | |
Collapse
|
20
|
Josselyn SA, Miller R, Beninger RJ. Behavioral effects of clozapine and dopamine receptor subtypes. Neurosci Biobehav Rev 1997; 21:531-58. [PMID: 9353791 DOI: 10.1016/s0149-7634(96)00051-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The atypical neuroleptic clozapine (CLZ) is an extremely effective antipsychotic that produces relatively few motoric side effects. However, CLZ displays limited antagonism at the dopamine (DA) D2 receptor, the receptor commonly thought to mediate the antipsychotic activity of neuroleptics. The mechanism of action behind the efficacy of CLZ remains to be determined. Miller, Wickens and Beninger [Progr. Neurobiol., 34, 143-184 (1990)] propose a "D1 hypothesis of antipsychotic action" that may explain the antipsychotic effects of CLZ. This hypothesis is built on the interactions between D2, cholinergic and D1 mechanisms in the striatum. These authors assert that although typical neuroleptics block D2 receptors, it is through an indirect action on D1 receptors that their antipsychotic action is manifest. The extra-pyramidal side effects produced by typical neuroleptics are hypothesized to be due to an indirect action on cholinergic receptors. It is argued that the anticholinergic properties of CLZ negate the D2 (motor side effects) action of CLZ, allowing CLZ to diminish psychotic symptoms through a direct action on D1 receptors. Thus, CLZ may function as a D1 receptor antagonist in behavioral paradigms. The current paper reviews and compares the behavioral profile of CLZ to those produced by D2- and D1-selective antagonists with specific reference to unconditioned and conditioned behaviors in order to more fully evaluate the "D1 hypothesis of CLZ action". Although the actions of CLZ remain unique, they do share some striking similarities with D1 receptor antagonists especially in tests of unconditioned behavior, possibly implicating the D1 receptor in the action of this antipsychotic drug.
Collapse
Affiliation(s)
- S A Josselyn
- Department of Psychology, University of Toronto, Ontario, Canada
| | | | | |
Collapse
|
21
|
Nakajima S, Patterson RL. The involvement of dopamine D2 receptors, but not D3 or D4 receptors, in the rewarding effect of brain stimulation in the rat. Brain Res 1997; 760:74-9. [PMID: 9237520 DOI: 10.1016/s0006-8993(97)00304-1] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
To identify the subtype of dopamine receptors critically involved in the rewarding effect of brain stimulation, four dopamine antagonists were intracranially injected in 25 rats. The importance of dopamine D1 receptors had been demonstrated previously by using SCH 23390, a highly selective D1 antagonist. Rats were implanted with electrodes into the medial forebrain bundle and cannulae into either one of the following structures: the nucleus accumbens, the vicinity of the islands of Calleja, or the ventral tegmental area, all ipsilateral to the electrodes. The animals were trained to press a bar for electrical stimulation, and the frequency-response functions were plotted before and after injection of each dopamine antagonist through the cannulae. Raclopride and haloperidol, which have high affinities for D2 receptors, reduced the rewarding effect after injection into any one of the three cannula sites. Neither (+)-UH232, a selective D3 antagonist, nor clozapine, a D4 antagonist, influenced the rewarding effect. The results suggest that dopamine D2, but not D3 or D4, receptors are critically involved in producing the rewarding effect of brain stimulation.
Collapse
Affiliation(s)
- S Nakajima
- Department of Psychology, Dalhousie University, Halifax, Nova Scotia, Canada.
| | | |
Collapse
|
22
|
Abstract
In recent years, considerable focus has been directed to understanding how drugs of abuse affect neuronal function at the molecular level. For example, repeated administration of stimulants or opiates can induce long-lasting alterations in gene expression, transcription factors, and signal transduction pathways. Our laboratory previously showed that intraaccumbens infusion of cholera toxin (CTX), which alters the Gs protein such that production of cyclic Adenosine Monophosphate (AMP) is upregulated, causes pronounced, long-lasting motor activation and sensitization to stimulants. In the present experiments, the effect of intraaccumbens infusion of cholera toxin on reward-related responding was investigated. The conditioned reinforcement (CR) paradigm was employed, which measures an animal's instrumental response to obtain presentation of a stimulus previously paired with a primary reward. When this stimulus supports acquisition of a new operant response (lever-pressing), it is termed a conditioned reinforcer (CR). In the first experiment, the effects of bilateral intraaccumbens infusion of CTX (100 ng/1 microliter) were examined on previously-established responding. CTX treatment resulted in enhanced responding for the CR. This enhancement developed over several days and reached its peak 3 days following infusion. In the second experiment, the influence of CTX was examined on acquisition of responding for the CR. The group treated with CTX (100 ng) discriminated between the CR and control (NCR) lever earlier than the vehicle-infused group, and showed greater levels of responding on the CR lever. In the third experiment, it was determined that infusion of CTX (300 ng bilaterally) into the anterior dorsal striatum did not affect levels of responding, although a later test with cocaine in these animals (25 mg/kg, intraperitoneally) (i.p.) indicated that they were capable of potentiated responding. These data are interpreted as evidence that the G(S) protein-cyclic AMP second messenger system within the nucleus accumbens is directly involved in reward-related behavior.
Collapse
Affiliation(s)
- A E Kelley
- Department of Psychiatry, University of Wisconsin-Madison Medical School 53719, USA
| | | |
Collapse
|
23
|
Mori T, Murase K, Tanaka J, Ichimaru Y. Biphasic effects of D3-receptor agonists, 7-OH-DPAT and PD128907, on the D1-receptor agonist-induced hyperactivity in mice. JAPANESE JOURNAL OF PHARMACOLOGY 1997; 73:251-4. [PMID: 9127821 DOI: 10.1254/jjp.73.251] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Effects of D3-receptor agonists, 7-OH-DPAT and PD128907, on the D1-receptor agonist SKF81297-induced hyperactivity in mice were examined. 7-OH-DPAT and PD128907 significantly suppressed the SKF81297-induced hyperactivity at low doses, but significantly potentiated the hyperactivity at high doses. These D3-agonists alone had no effect on the motor activity. A kappa-receptor agonist that reduces dopamine release had no effect on the SKF81297-induced hyperactivity. These results suggest that lower doses of 7-OH-DPAT and PD128907 may negatively influence the D1-receptor mediated behaviors via post synaptic D3-receptors. On the other hand, higher doses of these compounds may positively influence these behaviors via D2- or D3-receptors.
Collapse
Affiliation(s)
- T Mori
- Pharmaceutical Research Center, Meiji Seika Kaisha, Ltd., Yokohama, Japan
| | | | | | | |
Collapse
|
24
|
Depoortere R, Perrault G, Sanger DJ. Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl) 1996; 124:231-40. [PMID: 8740044 DOI: 10.1007/bf02246662] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
This study assessed the effects of IP injections of (+/-) 7-hydroxy-2(N,N-di-n-propylamino)tetralin (7-OH-DPAT), a dopamine agonist that has been reported to have preferential affinity for the dopamine D3 sub-type of receptor, on four behavioural procedures in the rat: 1) spontaneous locomotion, 2) electrical self-stimulation of the ventral tegmental area (VTA), using the curve-shift procedure 3) operant responding for food under a progressive-ratio (PR) schedule and 4) induction of stereotypies. The effects of (+/-) 7-OH-DPAT were compared to the effects of apomorphine, a non-specific DA agonist, and quinpirole, a selective D2/D3 agonist. All three dopamine agonists decreased locomotor activity at low doses (0.01-0.3 mg/kg), and only apomorphine had clear locomotor stimulant effects at the highest dose tested (3 mg/kg). The three drugs dose-dependently depressed VTA self-stimulation in a similar way, with low doses inducing a fairly parallel rightward shift of the frequency/rate curves and higher doses flattening the curves. In contrast, responding for food under the PR schedule appeared to be differentially affected by the three agonists: 7-OH-DPAT induced a biphasic effect, with a maximal decrease in lever-pressing at 0.1 mg/kg, followed by a return to baseline levels with increasing doses (0.3-3 mg/kg); quinpirole showed a tendency to decrease responding over the whole dose-range tested with a maximal effect of about 50% of baseline between 0.25 and 1 mg/kg, and apomorphine dose-dependently decreased responding, with rats ceasing to respond at 0.3 mg/kg. All three DA agonists induced stereotypies, but there was a difference in the maximal stereotypy score induced by each of the ligands: 7-OH-DPAT produced a lower maximal effect than quinpirole or apomorphine. This indicates that each of the three dopamine agonists preferentially induced different types of stereotypies. Together, these data suggest that the putative dopamine D3 agonist 7-OH-DPAT, at low doses, has depressant effects similar to those induced by low doses of the other two DA agonists. Differences in the behavioural effects of higher doses were, however, mostly observed in two procedures, PR responding and induction of stereotypies.
Collapse
|
25
|
Bustany P, Trenque T, Crambes O, Moulin M. Restoration of brain protein synthesis in mature and aged rats by a DA agonist, piribedil. Fundam Clin Pharmacol 1995; 9:458-68. [PMID: 8617410 DOI: 10.1111/j.1472-8206.1995.tb00521.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Brain ageing affects numerous cerebral metabolic pathways such as cerebral glucose consumption or protein synthesis rate. The pharmacological effect of a mixed D1-D2 dopaminergic agonist, piribedil, on this last metabolism is reported. Cerebral Protein Synthesis Rate (CPSR) was measured by the [35S]L-methionine autoradiographic procedure in 38 main brain regions of 11 and 26-month-old Wistar rats after a 2-month treatment per os at 9 and 30 mg/kg/day with piribedil. Mean decrease of CPSR was -21% during the 15-month ageing we followed, with important local variations. Mean CPSR increased with the two treatments, +25% in mature and +35% in aged rats. Treatments restored CPSR of aged rats to the exact mature subjects levels in quite all the brain regions. No dose-effect or asymetrical modification was statistically revealed for the two treatments. Metabolic increases involved particularly central brain gray structures, especially some DA-targeted brain nuclei concerned with behaviour and learning. This effect argued for a general metabotrophic effect of D1-D2 dopamine stimulation of the brain. The original pattern of local ageing of brain protein synthesis in rat was also incidentally reported. This was the first direct report of a wide and effective metabolic activation of CPSR in the brain during ageing by a curative dopaminergic agonist treatment.
Collapse
Affiliation(s)
- P Bustany
- Department of Pharmacology, CHU, Caen, France
| | | | | | | |
Collapse
|
26
|
Gilbert DB, Millar J, Cooper SJ. The putative dopamine D3 agonist, 7-OH-DPAT, reduces dopamine release in the nucleus accumbens and electrical self-stimulation to the ventral tegmentum. Brain Res 1995; 681:1-7. [PMID: 7552265 DOI: 10.1016/0006-8993(95)00247-n] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
The present experiments were designed to test further the idea that 7-OH-DPAT (7-hydroxy-N,N-di-n-propyl-2-aminotetralin), a putative dopamine (DA) D3 agonist, has effects at DA autoreceptors to reduce intracranial DA levels and to reduce behaviours that are DA-dependent. Rats were trained to respond on a self-stimulation protocol for electrical stimulation to the ventral tegmental area (VTA). Each press of a lever delivered a 0.5 s train of square wave, 1.5 ms duration, 100 Hz, 90-120 mA stimulation. Systemic administration of 7-OH-DPAT at 0.01-0.3 mg/kg i.p., quickly dose-dependently reduced responding. Electrical stimulation using similar parameters to those that supported self-stimulation were then applied to the VTA of anaesthetized rats. Fast cyclic voltammetry (FCV) revealed that this stimulation released DA in the nucleus accumbens (NAC). 7-OH-DPAT i.p. (0.1-3.0 mg/kg) quickly and potently reduced the size of the DA-generated voltammetric signal. This effect of 0.3 mg/kg 7-OH-DPAT was not blocked by sulpiride (60 mg/kg, i.p.) a D2-specific antagonist that may preferentially block D2 autoreceptors. These data are discussed with reference to the possibility that 7-OH-DPAT reduces the release of dopamine in the NAC, at D3, but not at D2, autoreceptors and that this in turn may reduce the rewarding effect of VTA stimulation.
Collapse
Affiliation(s)
- D B Gilbert
- Division of Psychology, School of Health and Human Sciences, University of Hertfordshire, Hatfield, UK
| | | | | |
Collapse
|
27
|
Ranaldi R, Beninger RJ. The effects of systemic and intracerebral injections of D1 and D2 agonists on brain stimulation reward. Brain Res 1994; 651:283-92. [PMID: 7922577 DOI: 10.1016/0006-8993(94)90708-0] [Citation(s) in RCA: 45] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
That dopamine (DA) plays a role in reward-related learning is well documented but the mechanisms through which it acts are not well understood. The present set of experiments investigated the role of DA receptor subtypes within DA-innervated forebrain regions in brain stimulation reward (BSR). Thirty-two rats were implanted with electrodes in the ventral tegmental area (VTA) and cannulae aimed at the caudal nucleus accumbens (NAcc), the caudate-putamen (CP) or cortex. Rate-frequency functions were determined by logarithmically decreasing the number of cathodal pulses in a stimulation train from a value that sustained maximal responding to one that did not sustain responding (thresholds). After BSR thresholds stabilized rats received treatments with DA agonists and their effects on thresholds were analyzed. Systemic treatments consisted of injections of (+)-amphetamine (1.0 mg/kg, i.p., 10 min before testing), the D2 agonist quinpirole (1.0 mg/kg, i.p., 10 min before testing), the novel D1 agonist A-77636 (3.0 mg/kg, s.c., 90 min before testing) or their vehicle (distilled H(2)0). Central treatments consisted of microinjections of quinpirole (0.3-10.0 micrograms/0.5 microliter) directly into the caudal NAcc, CP or cortex or A-77636 (30 micrograms/0.5 microliter) into the caudal NAcc or CP. Results showed that all three agonists, when injected systemically, significantly reduced the threshold frequency required for VTA BSR, indicating a potentiative effect on reward. Central injections of quinpirole in the caudal NAcc, CP or cortex produced significant increases in BSR thresholds indicative of reduced rewarding efficacy of stimulation. Central injections of A-77636 into the caudal NAcc, but not the CP, were associated with a reduction in VTA BSR thresholds, suggesting an increase in reward. These results suggest that stimulation of D1 or D2 receptors enhances the rewarding effect of brain stimulation. In the case of the systemic quinpirole enhancement of reward, the present results suggest that this may not occur in the caudal NAcc, CP or cortex. Finally, the present results suggest that D1 receptor stimulation in the caudal NAcc can facilitate reward-related learning.
Collapse
Affiliation(s)
- R Ranaldi
- Department of Psychology, Queen's University, Kingston, Canada
| | | |
Collapse
|